论文部分内容阅读
英夫利西作为一种针对肿瘤坏死因子的单克隆抗体,在儿童克罗恩病(CD)的治疗中已开始应用。许多大的随机对照研究已经显示其对儿童CD的诱导缓解和维持治疗具有良好的疗效,尤其是生长发育的恢复及降低肠切除术的概率,提高患儿的生活质量。英夫利西的治疗方案包括诱导缓解和维持治疗,前者在第0、2、6周以5 mg.kg-1的剂量静脉滴注,后者在缓解后每8周以相同剂量维持治疗。在治疗过程中要注意调整剂量和用药间隔,以避免失效。严重感染、输液反应、药物性红斑狼疮等不良反应也是重点关注的问题,目前英夫利西是否有致癌的可能性并不清楚,需要长期的随访观察。
Inflixib, a monoclonal antibody against tumor necrosis factor, has been used in the treatment of Crohn’s disease in children (CD). Many large randomized controlled studies have shown that it has a good effect on the induction of remission and maintenance of childhood CD, especially the recovery of growth and development and reduce the probability of intestinal resection, and improve the quality of life of children. Inflix’s treatment regimens include induction of remission and maintenance treatment, with the former being infused intravenously at doses of 5 mg.kg-1 at weeks 0, 2 and 6, and the latter being treated at the same dose every 8 weeks after remission. In the course of treatment should pay attention to adjust the dose and medication interval, in order to avoid failure. Serious infections, infusion reactions, drug-induced lupus erythematosus and other adverse reactions are also the focus of attention, the current Inflixir is not likely to cause cancer is not clear, the need for long-term follow-up observation.